Erectile dysfunction: management update

Fazio, Luke; Brock, Gerald
April 2004
CMAJ: Canadian Medical Association Journal;4/27/2004, Vol. 170 Issue 9, p1429
Academic Journal
DRAMATIC ADVANCES IN THE MANAGEMENT of erectile dysfunction have occurred over the past decade. Oral therapy with vasoactive agents has emerged as first-line treatment and has transformed both the manner in which the public views erectile dysfunction and the way health care providers deliver care. Whereas an ex-tensive investigation was previously common in the management of erectile dysfunction, recent treatment guidelines promote a more minimalist, goal-oriented approach. In this article, we re-view the physiology of erection, and the pathophysiology, diag-nosis and clinical management of erectile dysfunction. We also present the existing evidence for the efficacy of 3 phosphodi-esterase inhibitors, the most widely used class of agents for erec-tile dysfunction.


Related Articles

  • Erectile dysfunction: physiology, causes and patient management. Steggall, Martin J. // Nursing Standard;7/4/2007, Vol. 21 Issue 43, p49 

    This article examines the prevalence, causes, identification, assessment and treatment options for men with erectile dysfunction. Erectile dysfunction is thought to affect one in ten men across the UK and is often a consequence of pathology and/or pharmacology. Treatment can be offered to all...

  • Erectile Dysfunction What Are Some Treatment Options? Trapp, J. Douglas; Edelman, Steven // Diabetes Health;Feb2005, Vol. 14 Issue 2, p16 

    Presents information on erectile dysfunction. Description; Causes of reversible erectile dysfunction; Treatment.

  • Men prefer newer PDE-5 inhibitors in German study. Petrou-Binder, Stefanie // Urology Times;May2004, Vol. 32 Issue 7, p1 

    Investigates the efficacy of phosphodiesterase type-5 inhibitors (PDE-5) for erectile dysfunction in a study in a Germany. Number of men enrolled in the study; Number of PDE-inhibitors being evaluated; Quantity of tablets per drug taken by patients.

  • ED agent improves sexual pleasure in both partners. Binder, Stefanie Petrou // Urology Times;5/15/2005, Vol. 33 Issue 6, p25 

    Reports on a study which shows that the phosphodiesterase type-5 inhibitor vardenafil (Levitra) significantly improves sexual pleasure and treatment satisfaction in both men with erectile dysfunction (ED) and their partners. Estimated percentage of men over 40 years old who suffer from ED;...

  • PDE-5 inhibitor use highest after lap/robotic RP. Tennant, Scott // Urology Times;11/1/2008, Vol. 36 Issue 14, p10 

    The article reports on the findings of the study by researchers which examined the use of pharmacotherapy for erectile dysfunction (ED) at baseline and up to 18 months after surgery in the U.S. The study concluded that radical prostatectomy patients are most likely to use phosphodiesterase (PDE)...

  • Treating erectile dysfunction when PDE5 inhibitors fail. McMahon, Chelsea N.; Smith, Christopher J.; Shabsigh, Ridwan // BMJ: British Medical Journal (International Edition);3/11/2006, Vol. 332 Issue 7541, p589 

    The article looks at the treatment of erectile dysfunction after the oral drug phosphodiesterase type 5 (PDE5) inhibitors have failed. The response of patients who do not initially respond to PDE5 inhibitors may improve by educating patients about the right use of the drug, taking daily doses of...

  • Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms. Pimentel, H.; Wald, M.; Niederberger, C. // International Journal of Impotence Research;Mar/Apr2008, Vol. 20 Issue 2, p145 

    Erectile dysfunction is a prevalent disorder that not only affects men with the disorder but also their partners. Significant improvements in the sexual health of these couples have been achieved with the introduction of phosphodiesterase 5 (PDE5) inhibitors. Currently PDE5 inhibitors are used...

  • Role of Vardenafil in the Treatment of Patients with BPH in Salahaldin province. Abdul-Aziz, Mohammed Mohsin // Tikrit Medical Journal;Dec2010, Vol. 16 Issue 2, p71 

    Phosphodiesterase type 5 inhibitors are widely used to treat erectile dysfunction. The prevalence of comorbid ED and BPH-LUTS have generated interest in phosphodiesterase 5 (PDE5) inhibitors as a potential treatment for BPH-LUTS. to identify the role of Vardenafil -which is a PDE5 inhibitor - in...

  • Erectile dysfunction. Rees, Jonathan; Patel, Biral // BMJ: British Medical Journal (International Edition);3/11/2006, Vol. 332 Issue 7541, p593 

    The article provides advice to doctors on how to talk to and treat patients with possible erectile dysfunction. Erectile dysfunction can have psychogenic origins or organic causes and is a potential marker for generalized arteriosclerosis. The authors suggest that doctors examine the patient's...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics